Hot Deals:
5 star business 505.00 (1.00 %) a v thomas 12,800.00 (-1.54 %) aether industries 642.00 amol minechem 620.00 (1.64 %) anglo french 720.00 (-5.26 %) apl metals 44.00 (-2.22 %) aricent 595.00 (-0.83 %) arohan 197.00 (-3.90 %) assam carbon 243.00 (-2.80 %) atlas copco 5,050.00 (3.06 %) auckland 135.00 (-3.57 %) axles 135.00 (-3.57 %) b9 bira 830.00 (-1.19 %) balmer lawrie van leer 300.00 bharat hotels 162.00 (1.25 %) bikaji foods 360.00 (5.88 %) boat 1,030.00 (-5.50 %) c & s electric 400.00 capgemini 12,000.00 (-4.00 %) care health 145.00 (-3.33 %) carrier aircon 261.00 (-3.33 %) cial 185.00 (-0.54 %) csfbl 300.00 (-0.99 %) csk 178.00 (1.71 %) dalmia bharat refractories 95.00 (-4.04 %) delhivery 504.00 (-1.75 %) east india pharmaceutical 43.00 (2.38 %) eaton fluid 281.00 (0.36 %) electronica plastic 4,300.00 (2.38 %) elgi ultra 400.00 elofic 1,909.00 (0.47 %) epiroc 1,224.00 (-2.08 %) esl steel 46.00 (-2.13 %) fincare 69.50 (-0.71 %) fino paytech 165.00 (-2.94 %) frick india 4,140.00 (-3.72 %) gkn drive 1,150.00 (-0.95 %) godavari biorefineries 71.00 (1.43 %) hdbfsl 656.00 (-2.09 %) hdfc ergo 363.80 hdfc securities 13,700.00 (-2.14 %) hella india 158.00 (1.94 %) hero fincorp 800.00 (-5.88 %) hicks 2,100.00 (-2.55 %) hira ferro 140.00 (-6.67 %) honeywell electrical 4,240.00 (-0.24 %) icex 5.60 (-6.67 %) incred financial 100.00 india carbon 1,300.00 (1.56 %) india exposition mart 132.00 (-2.22 %) indian potash limited 1,405.00 (0.36 %) indofil industries 710.00 (-3.40 %) infinite computer 700.00 inkel 12.95 (-0.38 %) ixigo 111.00 (-5.13 %) jana sfbl 75.00 kial 120.00 (-2.44 %) klm axiva 10.00 kurlon enterprise 640.00 (-3.03 %) kurlon limited 450.00 (-2.17 %) lava 155.00 (-3.13 %) manipal hfsl 72.50 (0.69 %) manjushree technopack 1,150.00 (-3.36 %) martin and harris 2,070.00 (-5.91 %) merino 2,900.00 (-4.92 %) minosha 320.00 (-1.54 %) mitsubishi heavy industries 355.00 (1.43 %) mkcl 415.00 (1.22 %) mobikwik 555.00 (-7.50 %) mohan meakin 1,250.00 (-3.85 %) mohfl 11.50 (-4.17 %) msei 1.19 (-0.83 %) msil 54.00 (-1.82 %) ncdex 275.00 ncl buildtek 245.00 (-2.00 %) ncl holdings 48.00 (-4.00 %) nse 3,411.00 (-0.26 %) orbis financial 72.00 (2.86 %) oswal minerals 42.50 (1.19 %) otis 4,000.00 (-2.44 %) oyo rooms 100.00 (-9.91 %) panasonic appliances 306.00 (0.33 %) panasonic avc 29.10 (0.34 %) paymate india 630.00 (-10.00 %) pharm easy 54.00 (-1.82 %) philips domestic 565.00 (-4.24 %) philips india 1,150.00 (-2.21 %) pnb metlife 70.00 proyuga adtech 25.00 ramaraju surgical 540.00 (-4.42 %) reliance general insurance 340.00 resins plastics 406.00 (0.25 %) ring plus 350.00 (-3.05 %) rrl 3,000.00 (-1.64 %) sabmiller 400.00 (-1.23 %) satya micro 200.00 scottish assam 654.00 (0.62 %) shriram life 251.00 (0.40 %) signify 1,126.00 (0.09 %) smile microfin 80.00 (-2.44 %) sri vishnu shankar 640.00 (-1.54 %) sterlite power 900.00 (-1.10 %) studds 1,310.00 (-2.96 %) t stanes 675.00 tata tech 4,910.00 (0.20 %) tmbl 525.00 (1.94 %) trl krosaki 1,390.00 (-0.71 %) utkarsh coreinvest 166.00 (0.61 %) vikram solar 51.00 (2.00 %) xerox 261.00 (0.38 %)
×

anglo french drugs and industries Limited

720.00
-5.26 %
Scrip Name
ANGLO FRENCH
ISIN No.
INE570E01016
PAN No.
AAACA9756E
Face Value
10
No. of Outstanding Shares
1,291,500
Market Capitalization
92.99 Crore

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED UNLISTED ILLIQUIED SHARE


ANGLO – FRENCH DRUGS & INDUSTRIES LIMITED (AFDIL) is a pharmaceutical company established in 1923 and based in Bengaluru. The company is mainly engaged in the manufacturing of pharmaceutical formulations. Pharmaceutical formulation is a process in which different chemical substances, including the active drug, are mixed with each other to produce a final medicinal product.


Anglo–French Drugs & Industries Limited is one of the most prominent pharmaceutical company recognized not only in India but also at a global level. Anglo-French Drugs & Industries Limited is the first company to manufacture single vitamin injections and a combination of B-complex vitamins in India.


The company focuses mainly on Vitamins, Sleep inducing agents, Antiepileptics and antioxidants, cold and cough preparations, protein food supplements, antibiotics, anti-inflammatory drugs, digestive enzymes, and calcium supplements.


Anglo–French Drugs & Industries Limited serves around 75,000 medical practitioners in India annually. The company has a well-distributed network of 24 Clearing and Forwarding agents and 1600 stockists. The products of Anglo-French Drugs & Industries Limited are available at over 50,000 stores in India. The company has a presence in 16 countries across Eastern Europe, South East Asia & Africa.


Equity shares of Anglo–French Drugs & Industries Limited are listed on the Metropolitan Stock Exchange of India (MSEI).


INCORPORATION DETAILS


CIN

L24230KA1923PLC010205

Registration Date

01 February 1923

Category/Sub-category of the Company

Company limited by shares

Address of the Registered office and contact details

No.41, 3rd Cross, V Block, SSI Area, Rajajinagar, Bengaluru – 560010,

Karnataka, India

Tel No. 080-2315 6757

Name, Address and Contact Details of

Registrar and Transfer Agent, if any

Canbank Computer Services Limited,

J.P. Royale, 1st Floor, #218, 2nd Main

Sampige Road, Malleswaram,Bengaluru 560 003

Tel No.080-23469661/62

 

PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

Name and Description of main products/services

NIC Code of the product/service

% to the total turnover of the Company

Manufacturing of Pharmaceutical Formulations

21002

100%

 

BOARD OF DIRECTORS

Mr. Abhay Kanoria (Chairman & Managing Director)

Mr. Uddhav Kanoria (President & Whole-time Director)

Mr. Nirbhay Kanoria (Whole-time Director)

Mr. Sanatkumar Manjunath Shirali (Independent Director)

Mr. NalagathAhmedali (Independent Director)

Mrs. Neha Gada (Independent Director)

Mr. Shashikant N More (Nominee Director)

Dr.Rajeshwar B Smarta (Additional Independent Director)

Mr. Rakesh P Kanyadi (Additional Non-Executive Director)


PARTICULARS OF SUBSIDIARY COMPANIES

Name of the Company

% of shares held

Anglo-French Drugs & Industries Private Limited, Singapore

100%


SHAREHOLDING PATTERN

(As of 31-03-2020)

S. No.

Shareholders’ Name

Number of shares

% of total Shares of the company

1

Binod Kumar Kanoria(HUF)

200

0.017%

2

Prabhadevi Kanoria

3,450

0.297%

3

Abhay Kanoria

7,02,205

60.405%

4

Public Shareholding

4,56,645

39.28%


Total

11,62,500

100

 

INDUSTRY OUTLOOK

Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of global demand for various vaccines, 40% of generic demands in the USA, and 25% of all the medicines in the United Kingdom. Excellent Research & Development, low cost of labor, availability of management and technical personnel, and local equipment’s availability have helped India to manufacture pharma products at a very low cost.


The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID 19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.


Export of Pharmaceuticals products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat the covid patients in the initial stage of the covid-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.

After the onset of COVID 19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.

 

KEY FINANCIALS OF ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED (In Rs. Lakhs)

 

PARTICULARS

2021

2020

2019

2018

Revenue from Operations

15,378

13,018

12,914

11,140

EBITDA

1,636

1,238

694

-784

EBITDA margin

10.64%

9.51%

5.37%

-7.04%

Finance Cost

2,722

617

676

429

Depreciation

529

254

173

179

Other Income

102

155

70

101

Profit Before exceptional items and tax

963

522

-85

-1,291

Exceptional items

0

-156

0

0

Total Tax

212

55

0

-167

Profit After Tax (PAT)

751

311

-85

-1,124

PAT margin

4.88%

2.36%

-0.65%

-10.00%

EPS

61.94

26.72

-7.31

-96.69



BALANCE SHEET OF ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED(In Rs. Lakhs)

PARTICULARS

31st March 2021

31st March 2020

31st March 2019

ASSETS




NON CURRENT ASSETS




Tangible assets

1,358

1,527

1,475

Intangible assets

3

4

5

Financial assets

47

117

109

Other non-current assets

9

7

27

TOTAL NON CURRENT ASSETS

1,417

1,655

1,616

CURRENT ASSETS




Inventories

3,667

4,279

3,981

Trade receivables

3,626

2,581

2,950

Cash and Cash Equivalents

122

64

87

Other current financial assets

184

91

88

Tax assets

0

41

86

Other current assets

461

636

565

TOTAL CURRENT ASSETS

8,060

7,692

7,757

TOTAL ASSETS

9,477

9,347

9,373

EQUITY AND LIABILITIES




EQUITY




Equity share capital

129

116

116

Other equity

1,487

535

279

TOTAL EQUITY

1,607

651

395

LIABILITIES




NON CURRENT LIABILITIES




Borrowings

1,647

927

734

Other financial liabilities

311

311

309

Employee benefit obligations

106

115

105

Tax Liabilities

38

0

0

TOTAL NON CURRENT LIABILITIES

2,102

1,353

1,148

CURRENT LIABILITIES




Borrowings

2,324

3,073

3,797

Trade payables

2,256

2,865

2,564

Other financial liabilities

248

627

997

Employee benefir obligations

58

46

43

Current tax liabilities

34

0

0

Other current liabilities

848

733

429

TOTAL CURRENT LIABILITIES

5,768

7,344

7,830

TOTAL LIABILITIES

7,870

8,697

8,978

TOTAL EQUITY AND LIABILITIES

9,477

9,347

9,373

 

DIVIDEND HISTORY

Particulars

2020

2019

2018

Dividend (final + interim) (In Rs.)

Nil

Nil

Nil

Retained Earnings (Consolidated) (In Rs. Lakhs)

-123

-434

-337

 

 

 

PERFORMANCE OF THE COMPANY

Revenue from Operations of the company in FY 2021 was Rs.15,378 Lakhs, as against Rs.13,018 Lakhs in FY 2020. Revenue from Operations of the company increased by just Rs. 2,360 Lakhs, which is about18 % increase.


EBITDA of the company increased significantly by 32.15% from Rs. 1,238 Lakhs in FY 2020 to Rs. 1,636 Lakhs in FY 2021. EBITDA margins improved from 9.51% in FY 2020 to 10.64% in FY 2021.


In FY 2020, the company made a profit of Rs.311 Lakhs. In FY 2021 the company made a profit of Rs.751 Lakhs, i.e. an increase of 141.48%


The Current Ratio of the company as of 31st March 2021 was 1.40. The debt to equity ratio of the company as of 31st March 2021 was 2.47.


Book value per share of the company as of 31st March 2021 stood at Rs.138.24.


Anglo-French Drugs & Industries Limited has not given any dividends for the past 3 years.


During FY 2020, the Company launched two new products in the respiratory segment and one in the nutraceutical segment.






Powered by Froala Editor

Annual Reports

2020-21

Download

2019-20

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha Support Pallavi